Comparative Pharmacology
Head-to-head clinical analysis: QUIXIN versus ZAGAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUIXIN versus ZAGAM.
QUIXIN vs ZAGAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quixin (levofloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Sparfloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
One to two drops in affected eye(s) every 2 hours while awake, up to 8 times daily for 7-14 days.
600 mg intravenously once daily or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 6–8 hours in adults with normal renal function; prolonged in renal impairment (up to 20 hours if CrCl <30 mL/min).
10-12 hours; prolonged in renal impairment
Renal (approximately 70% unchanged in urine); biliary/fecal (~30%, partly as metabolites and unchanged drug).
Renal: 60-80% unchanged; biliary/fecal: 10-20%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic